Molecular Pharmacology (USA), Ltd.
Other OTCTotal Valuation
Molecular Pharmacology (USA), Ltd. carries a market capitalization of 403,818.00, placing it among publicly traded companies globally.
| Market Cap | 403,818.00 |
| Enterprise Value | N/A |
Share Statistics
Molecular Pharmacology (USA), Ltd. currently has 111.55M shares outstanding.
| Shares Outstanding | 111.55M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -21.29 |
| P/TBV Ratio | -21.26 |
| P/FCF Ratio | -408.07 |
| P/OCF Ratio | -408.07 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -976.34 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Molecular Pharmacology (USA), Ltd.'s stock has gained approximately 304% over the past 52 weeks. The 50-day moving average sits at 0.03, while the 200-day moving average is 0.04.
| Beta (5Y) | N/A |
| 52-Week Price Change | 304% |
| 50-Day Moving Average | 0.03 |
| 200-Day Moving Average | 0.04 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -105,052.00, while operating income came in at -105,084.00.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -105,084.00 |
| Pretax Income | -105,181.00 |
| Net Income | -105,181.00 |
| EBITDA | -105,052.00 |
| EBIT | -105,084.00 |
| Earnings Per Share (EPS) | 0.00 |
Balance Sheet
Total book value stands at -2.10M, with working capital of -2.10M providing operational flexibility.
| Cash & Cash Equivalents | 1,517.00 |
| Total Debt | N/A |
| Net Debt | -1,517.00 |
| Equity (Book Value) | -2.10M |
| Book Value Per Share | -0.02 |
| Working Capital | -2.10M |
Cash Flow
Molecular Pharmacology (USA), Ltd. produced -109,348.00 in operating cash flow over the past twelve months.
| Operating Cash Flow | -109,348.00 |
| Capital Expenditures | N/A |
| Free Cash Flow | -109,348.00 |
| FCF Per Share | 0.00 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 0.08 |
| FCF Yield | -0.25 |
Stock Splits
Molecular Pharmacology (USA), Ltd.'s most recent stock split took place on June 18, 2026 with a 50:1 split ratio.
| Last Split Date | 6/18/2026 |
| Split Ratio | 50:1 |
Scores
Molecular Pharmacology (USA), Ltd. posts an Altman Z-Score of -660.80, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -660.80 |